OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -38.62%8.67B | 96.53%2.21B | -66.00%1.68B | -18.62%3.24B | -62.24%1.53B | -13.49%14.12B | -73.86%1.12B | 97.02%4.95B | -43.05%3.98B | 61.44%4.06B |
Net income from continuing operations | -54.65%5.07B | -58.18%785M | -72.05%1.02B | -24.22%1.96B | -57.46%1.31B | -30.39%11.17B | -48.45%1.88B | -27.67%3.63B | -58.50%2.58B | 163.14%3.08B |
Operating gains losses | 12.41%-946M | 16.46%-198M | 62.50%-228M | -75.96%-366M | -470.37%-154M | 36.13%-1.08B | -72.99%-237M | 48.99%-608M | -2.97%-208M | 83.13%-27M |
Depreciation and amortization | 0.91%3.34B | -0.24%826M | 0.12%846M | 0.48%838M | 3.38%827M | 2.86%3.31B | 3.89%828M | 6.42%845M | 1.83%834M | -0.62%800M |
Deferred tax | -342.86%-124M | -77.78%8M | 56.98%-37M | -322.22%-60M | -600.00%-35M | -109.66%-28M | -90.86%36M | -273.91%-86M | 268.75%27M | 92.31%-5M |
Other non cash items | 42.24%-283M | 74.36%-20M | 83.45%-24M | 266.67%15M | 1.55%-254M | 23.91%-490M | -5.41%-78M | 55.52%-145M | 94.89%-9M | -279.41%-258M |
Change In working capital | 35.25%399M | 130.36%473M | -120.40%-216M | 10.51%568M | -252.14%-426M | 117.63%295M | -181.74%-1.56B | 153.84%1.06B | 188.76%514M | -58.15%280M |
-Change in receivables | -47.04%1.12B | -263.89%-944M | 221.97%2.14B | 263.94%882M | -125.18%-964M | 173.79%2.11B | 218.28%576M | -144.92%-1.76B | 67.49%-538M | 182.73%3.83B |
-Change in inventory | 44.79%-270M | -61.41%318M | 82.31%-107M | -102.59%-19M | 67.94%-462M | 37.87%-489M | -18.25%824M | -151.10%-605M | 147.11%733M | -1.26%-1.44B |
-Change in other working capital | 66.19%-448M | 137.15%1.1B | -165.83%-2.25B | -192.48%-295M | 147.46%1B | -167.19%-1.33B | -250.08%-2.96B | 342,200.00%3.42B | --319M | -105,450.00%-2.11B |
Cash from discontinued investing activities | 0 | 0 | ||||||||
Operating cash flow | -38.62%8.67B | 96.53%2.21B | -66.00%1.68B | -18.62%3.24B | -62.24%1.53B | -13.72%14.12B | -74.37%1.12B | 97.02%4.95B | -42.69%3.98B | 61.44%4.06B |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 149.56%1.53B | 131.85%307M | 567.59%2.03B | 101.93%17M | -0.98%-824M | -596.79%-3.1B | -93.57%-964M | -186.83%-435M | 19.12%-880M | -147.78%-816M |
Net PPE purchase and sale | -34.02%-2.53B | -52.26%-810M | -55.00%-651M | -1.25%-487M | -28.01%-585M | 21.90%-1.89B | 26.72%-532M | 40.09%-420M | 3.41%-481M | 7.68%-457M |
Net business purchase and sale | -64.88%-1.2B | 20.80%-575M | -84.80%45M | 84.80%-45M | ---622M | 11.25%-726M | 2.42%-726M | --296M | ---296M | --0 |
Net investment purchase and sale | 513.56%5.03B | 580.17%1.61B | 582.94%2.63B | 229.77%497M | 155.51%292M | -141.30%-1.22B | -72.12%237M | -157.25%-545M | 54.19%-383M | -126.55%-526M |
Net other investing changes | -68.70%231M | 40.35%80M | -96.58%8M | -81.43%52M | -45.51%91M | -19.26%738M | -53.28%57M | -6.40%234M | -12.50%280M | -24.77%167M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 149.56%1.53B | 131.85%307M | 567.59%2.03B | 101.93%17M | -0.98%-824M | -596.79%-3.1B | -93.57%-964M | -186.83%-435M | 19.12%-880M | -147.78%-816M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 12.48%-12.43B | -4.35%-3.31B | -21.87%-4.16B | 46.42%-1.99B | 23.80%-2.98B | -4.10%-14.21B | -20.22%-3.17B | 27.66%-3.41B | 5.39%-3.72B | -65.27%-3.91B |
Net issuance payments of debt | -169.22%-353M | -6,800.00%-1.17B | -3,963.16%-772M | 7,413.64%1.61B | -102.99%-17M | -53.59%510M | 22.73%-17M | 29.63%-19M | -15.79%-22M | -51.33%568M |
Net common stock issuance | 20.38%-9.16B | 45.35%-1.37B | 3.05%-2.7B | 5.56%-2.89B | 30.22%-2.21B | 1.45%-11.51B | -40.78%-2.5B | 28.40%-2.79B | 6.20%-3.06B | -15.02%-3.16B |
Cash dividends paid | 8.49%-1.15B | 6.11%-292M | 8.08%-273M | 8.23%-290M | 11.28%-299M | 1.41%-1.26B | 11.40%-311M | -4.21%-297M | -0.96%-316M | -2.12%-337M |
Net other financing activities | 9.40%-1.76B | -40.24%-474M | -33.01%-411M | -30.86%-424M | 53.44%-454M | -8.84%-1.95B | 30.31%-338M | 39.65%-309M | 4.71%-324M | -116.19%-975M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 12.48%-12.43B | -4.35%-3.31B | -21.87%-4.16B | 46.42%-1.99B | 23.80%-2.98B | -4.10%-14.21B | -20.22%-3.17B | 27.66%-3.41B | 5.39%-3.72B | -65.27%-3.91B |
Net cash flow | ||||||||||
Beginning cash position | -36.90%5.45B | -52.65%4B | -39.54%4.44B | -60.11%3.18B | -36.90%5.45B | 63.03%8.63B | 14.53%8.46B | -19.09%7.35B | 11.38%7.97B | 63.03%8.63B |
Current changes in cash | 29.83%-2.24B | 73.65%-793M | -139.66%-439M | 305.52%1.27B | -240.69%-2.27B | -195.45%-3.19B | -341.19%-3.01B | 165.12%1.11B | -131.88%-616M | -135.86%-666M |
End cash Position | -41.04%3.21B | -41.04%3.21B | -52.65%4B | -39.54%4.44B | -60.11%3.18B | -36.90%5.45B | -36.90%5.45B | 14.53%8.46B | -19.09%7.35B | 11.38%7.97B |
Free cash flow | -49.85%6.13B | 136.38%1.4B | -77.21%1.03B | -21.35%2.76B | -73.69%947M | -12.29%12.23B | -83.83%591M | 150.03%4.53B | -45.72%3.5B | 78.39%3.6B |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |